OKYO - חוב כולל להון OKYO Pharma

OKYO Pharma Limited (OKYO) develops therapies for retinal inflammation and dry eye disease, and this chart illustrates a total debt-to-equity ratio of 0.00. The company's competitive advantages are expanding due to patent-protected molecules and new oral medications. Simultaneously, the business is implementing ESG standards, optimizing center energy costs and the eco-friendly recycling of chemical waste in laboratories.

For OKYO Pharma Limited (OKYO), the total debt-to-equity chart reflects the balance between borrowed funds and owner assets, determining the company's degree of financial autonomy. The total liabilities-to-equity ratio measures default risk, which is critical for a non-cyclical biopharmaceutical business where resilience to macro shocks during the clinical trial stage depends exclusively on internal funding and scientific results.